摘要:
The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
摘要:
The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
摘要:
The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
摘要:
The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
摘要:
The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
摘要:
The invention relates to new methods for the treatment of oncological and fibrotic diseases comprising the combined administration of a receptor tyrosine kinase inhibitor in conjunction with a thrombin inhibitor.
摘要:
The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (VEGFRs) in conjunction with a thrombin inhibitor.
摘要:
The invention relates to the use of dabigatran etexilate of Formula (I) optionally in the form of the pharmaceutically acceptable salts thereof, as well as new medicament formulations for the treatment of tumours.
摘要:
The invention relates to a method for treating an overdosing with active substance dabigatran etexilate of formula I optionally in the form of the pharmaceutically acceptable salts thereof, comprising the administration of an effective amount of charcoal.